萨库比特里尔/瓦尔萨坦对心律失常和心力衰竭中左心室重塑的影响:一项观察性研究
Mauro Acquaro1, Laura Scelsi2, Beatrice Pasotti1
1Department of Molecular Medicine, University of Pavia, Corso Strada Nuova, 65, Pavia, Italy; Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Vascular pharmacology
|July 19, 2023
概括
萨库比特里尔/瓦尔沙坦显著减少了早发性心室综合体 (PVCs) 和心力衰竭中心室节奏的增加,心力衰竭患者减少了射出分数 (HFrEF). 然而,PVC减少与逆心脏重塑没有相关性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 心脏衰竭研究研究
背景情况:
- 关于萨库比特里尔/瓦尔萨坦在心力衰竭中降低射出分数 (HFrEF) 的抗节律作用,存在相互矛盾的文献.
- 评估对心律失常负担和心脏重塑的长期影响对于HFrEF管理至关重要.
研究的目的:
- 评估萨库比特里尔/瓦尔萨坦对HFrEF患者心律失常负担的长期影响.
- 在随访期间调查减少过早心室综合体 (PVC) 和逆心脏重塑之间的相关性.
主要方法:
- 分析了一组255名接受萨库比特里尔/瓦尔沙坦治疗的HFrEF患者.
- 24小时霍尔特ECG或ICD询问和心声回声仪在基线,12个月和24个月进行.
- 与心脏相关的住院病例在治疗前和随访期间进行了比较.
主要成果:
- 萨库比特里尔/瓦尔沙坦在12个月和24个月显著降低了24小时PVC的全球负担.
- 在患有双心室内心脏病的患者中,双心室内节奏显著增加.
- 在减少PVC和左心室逆向重塑 (LV-ESVi或LVEF) 之间没有发现显著的相关性.
- 在随访期间,与心力衰竭相关的住院病例显著减少.
结论:
- 在接受最佳治疗的HFrEF患者中,萨库比特里尔/瓦尔沙坦有效降低了PVC,并增加了双心脏节奏.
- 观察到的PVC减少与左心室逆向重塑没有相关性.
- 需要进一步的研究来阐明萨库比特里尔/瓦尔萨坦的潜在的直接抗心律失常机制.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:25Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
01:22Heart Failure Drugs: Diuretics
423
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
423
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16